{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:40:01Z","timestamp":1778758801218,"version":"3.51.4"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["IK2CX001495"],"award-info":[{"award-number":["IK2CX001495"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>The increasing prevalence of illicit stimulant use among those in opioid treatment programs poses a significant risk to public health, stimulant users have the lowest rate of retention and poorest outcomes among those in addiction treatment, and current treatment options are limited. Oxytocin administration has shown promise in reducing addiction-related behavior and enhancing salience to social cues. We conducted a randomized, double-blind, placebo-controlled clinical trial of intranasal oxytocin administered twice daily for 6 weeks to male Veterans with stimulant use disorder who were also receiving opioid agonist therapy and counseling (<jats:italic>n<\/jats:italic> = 42). There was no significant effect of oxytocin on stimulant use, stimulant craving, or therapeutic alliance over 6 weeks. However, participants receiving oxytocin (vs. placebo) attended significantly more daily opioid agonist therapy dispensing visits. This replicated previous work suggesting that oxytocin may enhance treatment engagement among individuals with stimulant and opioid use disorders, which would address a significant barrier to effective care.<\/jats:p>","DOI":"10.3389\/fpsyt.2021.804997","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T04:36:53Z","timestamp":1642394213000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Intranasal Oxytocin for Stimulant Use Disorder Among Male Veterans Enrolled in an Opioid Treatment Program: A Randomized Controlled Trial"],"prefix":"10.3389","volume":"12","author":[{"given":"Christopher S.","family":"Stauffer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salem","family":"Samson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Hickok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William F.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven L.","family":"Batki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"108193","DOI":"10.1016\/j.drugalcdep.2020.108193","article-title":"A systematic review and meta-analysis of medications for stimulant use disorders in patients with co-occurring opioid use disorders","volume":"216","author":"Chan","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"B2","doi-asserted-by":"publisher","first-page":"799","DOI":"10.15288\/jsad.2018.79.799","article-title":"Polysubstance use by stimulant users: health outcomes over three years","volume":"79","author":"Timko","year":"2018","journal-title":"J Stud Alcohol Drugs."},{"key":"B3","unstructured":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence\n            MattickRP\n            BreenC\n            KimberJ\n            DavoliM\n          10.1002\/14651858.CD002207.pub424500948Cochrane Database Syst Rev2014"},{"key":"B4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.drugalcdep.2018.08.029","article-title":"Twin epidemics: The surging rise of methamphetamine use in chronic opioid users","volume":"193","author":"Ellis","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1007\/s11606-019-05074-8","article-title":"Pharmacotherapy for cocaine use disorder\u2014a systematic review and meta-analysis","volume":"34","author":"Chan","year":"2019","journal-title":"J Gen Intern Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1111\/add.14755","article-title":"Pharmacotherapy for methamphetamine\/amphetamine use disorder\u2014a systematic review and meta-analysis","volume":"114","author":"Chan","year":"2019","journal-title":"Addiction."},{"key":"B7","doi-asserted-by":"publisher","first-page":"853","DOI":"10.15288\/jsad.2018.79.853","article-title":"Substance use disorders among veterans in a nationally representative sample: prevalence and associated functioning and treatment utilization","volume":"79","author":"Boden","year":"2018","journal-title":"J Stud Alcohol Drugs."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.3390\/ijms22052372","article-title":"Oxytocin signaling as a target to block social defeat-induced increases in drug abuse reward","volume":"22","author":"Ferrer-P\u00e9rez","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pbb.2013.11.019","article-title":"Oxytocin in learning and addiction: From early discoveries to the present","volume":"119","author":"Sarnyai","year":"2014","journal-title":"Pharmacol Biochem Behav."},{"key":"B10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40263-016-0313-z","article-title":"Targeting the oxytocin system to treat addictive disorders: rationale and progress to date","volume":"30","author":"Lee","year":"2016","journal-title":"CNS Drugs."},{"key":"B11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/bs.irn.2018.07.007","article-title":"Oxytocin and rodent models of addiction","volume":"140","author":"Leong","year":"2018","journal-title":"Int Rev Neurobiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/0269881112473788","article-title":"A brief history of oxytocin and its role in modulating psychostimulant effects","volume":"27","author":"Carson","year":"2013","journal-title":"J Psychopharmacol (Oxf)."},{"key":"B13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.physbeh.2017.10.020","article-title":"Effect of social housing and oxytocin on the motivation to self-administer methamphetamine in female rats","volume":"203","author":"Westenbroek","year":"2019","journal-title":"Physiol Behav."},{"key":"B14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.biopsych.2015.07.020","article-title":"The social salience hypothesis of oxytocin","volume":"79","author":"Shamay-Tsoory","year":"2016","journal-title":"Biol Psychiatry."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1534765608319085","article-title":"The attachment characteristics of combat veterans with PTSD","volume":"14","author":"Renaud","year":"2008","journal-title":"Traumatology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"146761","DOI":"10.1016\/j.brainres.2020.146761","article-title":"The role of oxytocin in alcohol and drug abuse","volume":"1736","author":"King","year":"2020","journal-title":"Brain Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1097\/FBP.0000000000000258","article-title":"Oxytocin for the treatment of drug and alcohol use disorders","volume":"27","author":"Lee","year":"2016","journal-title":"Behav Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3109\/16066359.2016.1173682","article-title":"two-week pilot study of intranasal oxytocin for cocaine-dependent individuals receiving methadone maintenance treatment for opioid use disorder","volume":"24","author":"Stauffer","year":"2016","journal-title":"Addict Res Theory."},{"key":"B19","doi-asserted-by":"publisher","first-page":"108059","DOI":"10.1016\/j.jsat.2020.108059","article-title":"Oxytocin-enhanced group therapy for methamphetamine use disorder: randomized controlled trial","volume":"116","author":"Stauffer","year":"2020","journal-title":"J Subst Abuse Treat."},{"key":"B20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/10503300500352500","article-title":"Development and validation of a revised short version of the working alliance inventory","volume":"16","author":"Hatcher","year":"2006","journal-title":"Psychother Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"21004","DOI":"10.1038\/s41598-021-99957-8","article-title":"Oxytocin increases physiological linkage during group therapy for methamphetamine use disorder: a randomized clinical trial","volume":"11","author":"Thorson","year":"2021","journal-title":"Sci Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1037\/cou0000386","article-title":"Oxytocin as a biomarker of the formation of therapeutic alliance in psychotherapy and counseling psychology","volume":"67","author":"Zilcha-Mano","year":"2020","journal-title":"J Couns Psychol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/00005053-199912000-00006","article-title":"Lifetime severity index for cocaine use disorder (LSI-Cocaine): a predictor of treatment outcomes","volume":"187","author":"Hser","year":"1999","journal-title":"J Nerv Ment Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.pbb.2013.09.005","article-title":"Individual differences underlying susceptibility to addiction: role for the endogenous oxytocin system","volume":"119","author":"Buisman-Pijlman","year":"2014","journal-title":"Pharmacol Biochem Behav."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.4088\/JCP.14ac09437","article-title":"Can we bottle psychosocial treatments for addiction? The Role of Oxytocin: (ASCP Corner)","volume":"75","author":"Stauffer","year":"2014","journal-title":"J Clin Psychiatry."},{"key":"B26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.psychres.2015.07.064","article-title":"Effects of adverse childhood experiences on the association between intranasal oxytocin and social stress reactivity among individuals with cocaine dependence","volume":"229","author":"Flanagan","year":"2015","journal-title":"Psychiatry Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"104752","DOI":"10.1016\/j.psyneuen.2020.104752","article-title":"Examining sex, adverse childhood experiences, and oxytocin on neuroendocrine reactivity in smokers","volume":"120","author":"Hood","year":"2020","journal-title":"Psychoneuroendocrinology."},{"key":"B28","author":"Sheehan","year":"2014","journal-title":"Mini international neuropsychiatric interview\u2013version 7.0. 0 DSM-5"},{"key":"B29","article-title":"The addiction severity index-\u2018\u2018Lite\u201d (ASI-\u201cLite\u201d)","author":"McLellan","year":"1997","journal-title":"Center for the Studies of Addict"},{"key":"B30","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0749-3797(98)00017-8","article-title":"Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults: the Adverse Childhood Experiences (ACE) Study","volume":"14","author":"Felitti","year":"1998","journal-title":"Am J Prev Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41380-020-00864-7","article-title":"Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research","volume":"26","author":"Quintana","year":"2021","journal-title":"Mol Psychiatry."},{"key":"B32","article-title":"The reliability of the Timeline Followback (TLFB) method as applied to drug, cigarette, and the cannabis use","author":"Sobell","year":"1996","journal-title":"Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.addbeh.2010.08.013","article-title":"How good is fine-grained Timeline Follow-back data? Comparing 30-day TLFB and repeated 7-day TLFB alcohol consumption reports on the person and daily level","volume":"35","author":"Hoeppner","year":"2010","journal-title":"Addict Behav."},{"key":"B34","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.addbeh.2014.11.020","article-title":"On the invariance of the Stimulant Craving Questionnaire (STCQ) across cocaine and methamphetamine users","volume":"42","author":"Northrup","year":"2015","journal-title":"Addict Behav."},{"key":"B35","doi-asserted-by":"crossref","unstructured":"Therapeutic Alliance and Outcome of Psychotherapy: Historical Excursus, Measurements, and Prospects for Research2\n            ArditoRB\n            RabellinoD\n          10.3389\/fpsyg.2011.0027022028698Front Psychol2011","DOI":"10.3389\/fpsyg.2011.00270"},{"key":"B36","year":"2020","journal-title":"R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA."},{"key":"B38","doi-asserted-by":"publisher","first-page":"h4672","DOI":"10.1136\/bmj.h4672","article-title":"Understanding the Hawthorne effect","volume":"351","author":"Sedgwick","year":"2015","journal-title":"BMJ."},{"key":"B39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/add.14793","article-title":"Dropout rates of in-person psychosocial substance use disorder treatments: a systematic review and meta-analysis","volume":"115","author":"Lappan","year":"2020","journal-title":"Addiction."},{"key":"B40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11414-007-9093-z","article-title":"Individual and Program Predictors of Attrition from VA Substance Use Treatment","volume":"36","author":"Curran","year":"2009","journal-title":"J Behav Health Serv Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"108278","DOI":"10.1016\/j.jsat.2021.108278","article-title":"Substance use predictors of attendance among veterans in integrated PTSD and alcohol use disorder treatment","volume":"124","author":"Kline","year":"2021","journal-title":"J Subst Abuse Treat."},{"key":"B42","doi-asserted-by":"publisher","first-page":"001088","DOI":"10.1002\/14651858.CD001088.pub4","article-title":"Psychosocial interventions for people with both severe mental illness and substance misuse","volume":"12","author":"Hunt","year":"2019","journal-title":"Cochrane Database Syst Rev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.addbeh.2005.05.024","article-title":"Pretreatment and during treatment risk factors for dropout among patients with substance use disorders","volume":"31","author":"McKellar","year":"2006","journal-title":"Addict Behav."},{"key":"B44","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0272-7358(92)90092-M","article-title":"Dropping out of substance abuse treatment: a clinically oriented review","volume":"12","author":"Stark","year":"1992","journal-title":"Clin Psychol Rev."},{"key":"B45","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1001\/archpsyc.1981.01780330033003","article-title":"Treatment for drug abuse: follow-up outcomes and length of time spent","volume":"38","author":"Simpson","year":"1981","journal-title":"Arch Gen Psychiatry."},{"key":"B46","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1176\/appi.ajp.2011.11071121","article-title":"Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial","volume":"169","author":"Tiihonen","year":"2012","journal-title":"Am J Psychiatry."},{"key":"B47","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.1073\/pnas.1702725114","article-title":"Oxytocin under opioid antagonism leads to supralinear enhancement of social attention","volume":"114","author":"Dal Monte","year":"2017","journal-title":"Proc Natl Acad Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.tics.2019.10.004","article-title":"Combinatorial oxytocin neuropharmacology in social cognition","volume":"24","author":"Fan","year":"2020","journal-title":"Trends Cogn Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cct.2019.05.002","article-title":"Design of a randomized controlled trial examining the efficacy of oxytocin to enhance alcohol behavioral couple therapy","volume":"82","author":"Flanagan","year":"2019","journal-title":"Contemp Clin Trials."},{"key":"B50","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0006-8993(83)90478-X","article-title":"Penetration of neurohypophyseal hormones from plasma into cerebrospinal fluid (CSF): Half-times of disappearance of these neuropeptides from CSF","volume":"262","author":"Mens","year":"1983","journal-title":"Brain Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nature00822","article-title":"Intracellular calcium stores regulate activity-dependent neuropeptide release from dendrites","volume":"418","author":"Ludwig","year":"2002","journal-title":"Nature."},{"key":"B52","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1677\/joe.0.1020063","article-title":"Release of oxytocin and vasopressin by magnocellular nuclei in vitro: specific facilitatory effect of oxytocin on its own release","volume":"102","author":"Moos","year":"1984","journal-title":"J Endocrinol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1038\/srep03440","article-title":"Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans","volume":"3","author":"Striepens","year":"2013","journal-title":"Sci Rep."},{"key":"B54","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/j.1365-2826.2005.01346.x","article-title":"u-Opioid receptor preferentially inhibits oxytocin release from neurohypophysial terminals by blocking R-type Ca2+ Channels","volume":"17","author":"Ortiz-Miranda","year":"2005","journal-title":"J Neuroendocrinol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1159\/000124168","article-title":"Effects of opioid agonists and antagonists on oxytocin and vasopressin release in vitro","volume":"41","author":"Bicknell","year":"1985","journal-title":"Neuroendocrinology."},{"key":"B56","unstructured":"The role of family expressed emotion and perceived social support in predicting addiction relapse20\n            AtadokhtA\n            HajlooN\n            KarimiM\n            NarimaniM\n          10.5812\/ijhrba.2125025883918Int J High Risk Behav Addict42015"},{"key":"B57","doi-asserted-by":"publisher","first-page":"100188","DOI":"10.1016\/j.abrep.2019.100188","article-title":"An inverse relationship between perceived social support and substance use frequency in socially stigmatized populations","volume":"10","author":"Rapier","year":"2019","journal-title":"Addict Behav Rep."},{"key":"B58","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0031-9384(03)00148-3","article-title":"Is social attachment an addictive disorder?","volume":"79","author":"Insel","year":"2003","journal-title":"Physiol Behav."},{"key":"B59","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrn.2016.67","article-title":"Time to connect: bringing social context into addiction neuroscience","volume":"17","author":"Heilig","year":"2016","journal-title":"Nat Rev Neurosci."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.804997\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T04:36:58Z","timestamp":1642394218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.804997\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":59,"alternative-id":["10.3389\/fpsyt.2021.804997"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.804997","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]},"article-number":"804997"}}